ARIX:LSE-Arix Bioscience plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 159.00

Change

-0.50 (-0.31)%

Market Cap

GBX 0.21B

Volume

0.17M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCM:LSE HUTCHMED (China) Limited

-35.00 (-6.17%)

GBX4.90B 17.41 N/A
GNS:LSE Genus plc

+10.00 (+0.18%)

GBX3.73B 78.75 40.06
ABC:LSE Abcam plc

+2.00 (+0.13%)

GBX3.47B 212.50 51.62
OXB:LSE Oxford Biomedica plc

+156.00 (+10.55%)

GBX1.22B N/A 274.91
PRTC:LSE PureTech Health plc

+0.50 (+0.14%)

GBX1.05B 225.00 24.65
ERGO:LSE Ergomed plc

+65.00 (+4.71%)

GBX0.67B 71.88 37.11
SLN:LSE Silence Therapeutics plc

N/A

GBX0.48B N/A N/A
SNG:LSE Synairgen plc

-1.20 (-0.73%)

GBX0.33B N/A N/A
REDX:LSE Redx Pharma Plc

+5.00 (+4.95%)

GBX0.28B N/A N/A
AVCT:LSE Avacta Group Plc

+19.20 (+17.98%)

GBX0.27B N/A N/A

ETFs Containing ARIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.40% 23% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.40% 23% F 6% F
Trailing 12 Months  
Capital Gain 54.37% 71% C- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.37% 71% C- 79% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.40% 29% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.40% 29% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 58.95% 71% C- 25% F
Risk Adjusted Return 14.25% 29% F 34% F
Market Capitalization 0.21B 74% C 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.76 92% A- 82% B-
Price/Book Ratio 0.76 98% A+ 86% B
Price / Cash Flow Ratio -30.81 76% C 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 14.61% 93% A 66% D
Return on Invested Capital -2.76% 83% B 34% F
Return on Assets 12.58% 98% A+ 88% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.59 29% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.